Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $8.36 and last traded at $8.87, with a volume of 447122 shares trading hands. The stock had previously closed at $9.93.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on UPB. TD Cowen began coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They issued a "buy" rating on the stock. Piper Sandler began coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They issued an "overweight" rating and a $75.00 price target on the stock. William Blair began coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They issued an "outperform" rating on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They issued an "overweight" rating and a $38.00 price target on the stock.
Check Out Our Latest Analysis on Upstream Bio
Upstream Bio Stock Down 7.2 %
The stock's 50-day moving average price is $15.42.
Upstream Bio (NASDAQ:UPB - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($6.96) EPS for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The business had revenue of $0.61 million during the quarter, compared to analysts' expectations of $0.83 million. As a group, equities analysts expect that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.
Hedge Funds Weigh In On Upstream Bio
Several large investors have recently bought and sold shares of UPB. US Bancorp DE acquired a new stake in Upstream Bio in the fourth quarter valued at $27,000. Rhumbline Advisers bought a new stake in shares of Upstream Bio in the 4th quarter valued at $275,000. Bank of New York Mellon Corp bought a new stake in shares of Upstream Bio in the 4th quarter valued at $607,000. Moody Aldrich Partners LLC bought a new stake in shares of Upstream Bio in the 4th quarter valued at $1,229,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Upstream Bio in the 4th quarter valued at $2,225,000.
Upstream Bio Company Profile
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
